Cargando…
The Antiviral Effect of Nirmatrelvir/Ritonavir during COVID-19 Pandemic Real-World Data
Introduction: Vaccination against SARS-CoV-2 and the prevalence of Omicron variants have reduced the risk of the severe clinical progress of COVID-19. However, the risk of breakthrough infections has increased, and early administration of an effective antiviral treatment is significant in order to p...
Autores principales: | Petrakis, Vasilios, Rafailidis, Petros, Trypsianis, Grigorios, Papazoglou, Dimitrios, Panagopoulos, Periklis |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10144059/ https://www.ncbi.nlm.nih.gov/pubmed/37112956 http://dx.doi.org/10.3390/v15040976 |
Ejemplares similares
-
The Impact of the COVID-19 Pandemic on Antimicrobial Resistance and Management of Bloodstream Infections
por: Petrakis, Vasilios, et al.
Publicado: (2023) -
Real-world use of nirmatrelvir–ritonavir: who benefits?
por: Molina, Kyle C, et al.
Publicado: (2023) -
Nirmatrelvir-ritonavir for COVID-19
por: McDonald, Emily G, et al.
Publicado: (2022) -
Nirmatrelvir and ritonavir for COVID-19
Publicado: (2022) -
Greek Remdesivir Cohort (GREC) Study: Effectiveness of Antiviral Drug Remdesivir in Hospitalized Patients with COVID-19 Pneumonia
por: Petrakis, Vasilis, et al.
Publicado: (2022)